Therapeutics Emerging Therapies

A Case Series on Natural Conceptions Resulting in Ongoing Pregnancies in Menopausal and Prematurely Menopausal Women Following Platelet-Rich Plasma Treatment

Pantos K, Simopoulou M, Pantou A, Rapani A, Tsioulou P, Nitsos N, Syrkos S, Pappas A, Koutsilieris M, Sfakianoudis K

Published July 5, 2019 Cell Transplantation, 28(9-10), 1333-1340
DOI 10.1177/0963689719859539 PMID 31271054 PMC PMC6767896

RRM Academy Synopsis

Ovarian Platelet-Rich Plasma Preceded Pregnancy in Menopausal Women

All three women conceived naturally within two to six months of treatment. Each had received a single autologous ovarian platelet-rich plasma injection. All three pregnancies were ongoing and complication-free at the time of reporting. The three women, two with premature ovarian failure, aged 40 and 27, and one menopausal, aged 46, had each had failed IVF and declined oocyte donation.

Key Findings

  • The case series included three women: two with premature ovarian failure, aged 40 and 27, and one menopausal woman, aged 46, each with no menstrual cycle for 12 to 26 months.
  • All three women resumed menstruation after a single ovarian platelet-rich plasma injection, with cycles returning between one and two months after treatment.
  • Each woman conceived naturally, without IVF, between two and six months after the PRP injection.
  • At the time of reporting, all three pregnancies were ongoing and complication-free, at 26 to 37 weeks of gestation with normal first- and second-trimester screening.
  • Follow-up ultrasounds found small ovarian follicles at some point in all three women, where none had been detectable before treatment.

Interpretation

This is a case series describing three women who each received one autologous ovarian platelet-rich plasma injection. The authors call it the first published report of natural conception and an ongoing pregnancy after this treatment in menopausal and prematurely menopausal women. They say the approach is worth more study for women who want to conceive with their own eggs. The authors note that growth factor levels vary between patients, and that this variability was not recorded in the current study. They call for randomized controlled trials to confirm PRP's effectiveness in this patient group, building on these results.

RRM Context

Injecting PRP into the ovary is an experimental step outside NaProTechnology and fertility awareness-based care. Still, these three women shared a goal with restorative reproductive medicine: conceiving with their own eggs. They had declined oocyte donation and reached that goal in this research setting.

Abstract

Since the introduction of autologous platelet-rich plasma (PRP) in medical practice, various studies have documented that implementing PRP can enhance healing and the anti-aging process, employing angiogenesis regeneration due to the multiple growth factors and cytokines involved. Numerous reports have shown promising results with the use of PRP in ovarian treatment, regarding ovarian regeneration and reactivation of folliculogenesis. This case series reports on two women with premature ovarian failure (POF) aged 40 and 27 years, respectively, and one menopausal woman aged 46 years. All patients presented with lack of menstrual cycle for over a year. The women reported previous failed in vitro fertilization (IVF) attempts, and, after rejecting the option of oocyte donation, they opted for the approach of autologous ovarian PRP treatment. Following PRP treatment, the three patients were invited to conceive naturally. The primary outcome was the restoration of menstruation following autologous ovarian PRP treatment, as well as an improvement in hormonal profile, a decrease in follicle-stimulating hormone (FSH) levels, and a concurrent increase in anti-Müllerian hormone (AMH) levels. Further to that, our patients achieved pregnancy through natural conception within 2-6 months following PRP treatment, resulting in currently ongoing complication-free clinical pregnancies - a first report in the literature for menopausal and POF patients. Implementation of PRP should be further investigated through randomized controlled trials (RCTs), as it may hold the key to successful treatment for a certain cohort of patients exploring reproductive treatment options following menopause.

Topics

By this author

Related research

Therapeutics › Emerging Therapies › Platelet-Rich Plasma · Reproductive Endocrinology › Ovarian Hormones › Estrogen · Longevity and Reproductive Aging › Reproductive Aging › Ovarian Aging
Konstantinos Pantos, Mara Simopoulou, Agni Pantou, Anna Rapani, Petroula Tsioulou, Nikolaos Nitsos, Stephen Syrkos, Athanasios Pappas, Michael Koutsilieris, Konstantinos Sfakianoudis
K Pantos, M Simopoulou, A Pantou, A Rapani, P Tsioulou, N Nitsos, Steve Syrkos, S Syrkos, A Pappas, Mike Koutsilieris, M Koutsilieris, K Sfakianoudis
PMID 31271054 31271054 DOI 10.1177/0963689719859539 10.1177/0963689719859539 Pantos et al. 2019, Pantos 2019